Pacific Biosciences Of California (PACB) Enterprise Value (2010 - 2026)

Pacific Biosciences Of California has reported Enterprise Value for 17 years, with the latest figure at $285.3 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 394.44% year-over-year to $285.3 million in Q2 2026; TTM through Jun 2026 was $285.3 million, a 394.44% increase from a year earlier, with the FY2025 full-year figure at $285.2 million, up 91.56% from the prior year.
• Enterprise Value was $285.3 million for Q2 2026 at Pacific Biosciences Of California, up from $133.9 million in the prior quarter.
• The five-year high for Enterprise Value was $2.5 billion in Q2 2023, with the low at -$136.5 million in Q2 2024.
• Average Enterprise Value over 5 years is $664.5 million, with a median of $285.2 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 2553.46% in 2023, then sank 105.46% in 2024.
• Over 5 years, Enterprise Value stood at $1.1 billion in 2022, then surged by 84.65% to $2.0 billion in 2023, then plunged by 92.54% to $148.9 million in 2024, then soared by 91.56% to $285.2 million in 2025, then gained by 0.05% to $285.3 million in 2026.
• The last three Enterprise Value figures came in at $285.3 million (Q2 2026), $133.9 million (Q1 2026), and $285.2 million (Q4 2025), per Business Quant data.